| INTRODUCTION
Proton pump inhibitors (PPIs, eg, omeprazole) have superior acid suppressing efficacy compared to histamine-2 receptor antagonists (H2RAs, eg, famotidine) and are considered to be the treatment of choice for gastrointestinal (GI) ulceration in dogs and cats. [1] [2] [3] However, the aggressive acid suppression provided by PPIs may not always be desired. Famotidine continues to be widely used in veterinary medicine because it can provide immediate clinical relief and can be administered with a full meal, unlike omeprazole which takes days to reach peak onset of action and must be administered on an empty stomach. 4 Veterinarians also perceive that famotidine alleviates stomach upset in animals with chronic diseases, such as chronic kidney disease (CKD) and chronic enteropathies. For example, in 2 large retrospective studies of cats with CKD, famotidine was 1 of the top medications prescribed. 5, 6 The efficacy of prolonged famotidine administration can decrease over time in humans, dogs, and cows. 4, 7, 8 In dogs, daily oral famotidine administration resulted in good acid suppression on days 1 and 2 but was no better than placebo at increasing intragastric pH by day 12. 7 In a study of human subjects, a diminished acid suppressant effect appeared to be dependent on daily H2RA
Abbreviations: ANOVA, analysis of variance; GI, gastrointestinal; H2RA, histamine-2 receptor antagonist; MPT, mean percentage time; PPI, proton pump inhibitor; RAH, rebound acid hypersecretion.
administration, whereas twice daily every second day administration did not result in tolerance. 9 To our knowledge, the effects of oral famotidine administration on intragastric pH in cats over time have not been reported. Because famotidine is a commonly administered treatment in cats, determination if daily famotidine administration results in diminished acid suppression in cats is of interest. Our study objectives were to determine if twice daily oral famotidine administration led to tolerance and if the development of this effect required daily drug administration in cats.
We hypothesized that daily oral famotidine administration would lead to a diminished effect on gastric pH over time.
| MATERIALS AND METHODS

| Study animals
The subjects of this study were 16 healthy adult cats from a research colony at the University of Tennessee (12 intact females, 1 spayed female, 2 castrated males, and 1 intact male), aged 3.2-4.2 years (median, 3.8 years), and weighing 3.0-6.4 kg (median, 4.6 kg). None of the cats showed clinical signs of GI disease, and they were deemed healthy based on history and available historical blood test results as well as normal physical examination, normal baseline blood test results (CBC, serum biochemistry profile, urinalysis) and negative fecal examinations using zinc and sugar sulfate centrifugation flotation methods performed within 6 months of study entry. The number of cats (n = 16) selected was based on a sample size calculation using a study evaluating the effect of intermittent administration of an H2RA blocker in people. 10 By means of a high correlation (0.8) and power = 0.8, 14 cats were needed to identify a change of 13% in mean intragastric pH between treatment groups. An additional 2 cats were enrolled to account for the possibility of study dropout. Animals were cared for according to the principles outlined in the NIH Guide for the Care and Use of Laboratory Animals (approved IACUC protocol for this study #2312-0115).
| Study design
In a randomized, open label, 2-way crossover study design, all cats were treated using PO administered famotidine (Famotidine; Merck Consumer Pharmaceuticals Company, Deerfield, Illinois) at a dosage of 0.5-1.24 mg/kg (median, 0.87 mg/kg), twice daily ("Group 1") or twice daily every second day (twice daily q48h; "Group 2") for 14 consecutive days. The goal was to dose famotidine as close to 0.5-1 mg/kg q12h as possible. This dose was achieved by administering one-quarter to one-half tablet and was kept consistent across treatment arms. Cats were randomized to a treatment schedule by a random number generator, so A period of 7 weeks separated treatment groups with no medications administered during this period.
| Intragastric pH monitoring
The Bravo pH monitoring system (Bravo pH capsule with delivery system; Given Imaging, Duluth, Georgia) was placed by radiographic guidance under sedation as previously described. 11 All pH capsules and receivers were calibrated as previously described according to the manufacturer's instructions. The pH capsule was then blindly introduced transorally into the proximal stomach as previously described. 11 Sedation was reversed with 10 μg/kg atipamezole (Antisedan 5 mg/mL injection; Orion Pharma, Espoo, Finland) IM after pH capsule placement. The pH capsule placement was repeated in the same manner on day 11 of the treatment period ( Figure 1 ).
| pH recordings
Intragastric pH recordings were obtained telemetrically at 6-second sampling intervals. Twenty-four-hour intragastric pH recording was 
| Serum gastrin concentrations
At baseline (day 0) and on treatment days 2 and 11, 3 mL of blood was obtained by venipuncture of the jugular or medial saphenous vein after an overnight fast and after receiving sedation on days 0 and 11 and after an overnight fast without sedation on day 2. Serum was collected from clotted blood using serum clot activator tubes after centrifugation at 250g and stored in cryovials at −80 C. After study completion, the serum was shipped on dry ice to the Gastrointestinal Laboratory at
Texas A&M University for measurement of serum gastrin concentrations. Serum gastrin concentrations were measured using an automated chemiluminescent, enzyme-labeled immunometric assay (Immulite 2000; Siemens Healthcare Diagnostics, Malvern, Pennsylvania) as previously described. 13 
| Statistical analysis
Mean pH and mean percentage time (MPT) intragastric pH ≥3 and ≥4
were calculated using the manufacturer software (Polygram Net Software; Given Imaging, Yoqneam, Israel). Statistical analysis was performed using commercial software (SAS software, version 9.54, Cary, North Carolina 27 513, USA, Release TS1M5). A 2-factor repeatedmeasures mixed-effects crossover design and corresponding analysis of variance (ANOVA) were performed to evaluate mean intragastric pH and MPT that intragastric pH were ≥3 and 4 for treatment, time (day of treatment), and period differences. To be conservative, a value of 9.9 ng/L was assigned to all gastrin data below the assay's limit of detection (<10 ng/L). Serum gastrin concentrations and MPT that intragastric pH was ≥4 were then log transformed and analyzed by repeated-measures mixed model ANOVA to evaluate for treatment, time, treatment by time interaction, and period differences. Two time points (1, 13) were observed for mean intragastric pH and MPT that intragastric pH were ≥3 and 4, and 3 time points were observed for serum gastrin concentrations (days 0, 2, and 11 3 | RESULTS
| Capsule placement and pH monitoring
Of 64 pH capsules, 63 were successfully attached to the gastric fundic mucosa. On 1 occasion, the capsule failed to deploy from the delivery device (day 0, Group 2). This was thought to be attributable to a malfunction of the delivery device itself. The capsule was readministered PO and stayed in the stomach for days 0 and 1, and, therefore, this data was included in the statistical analysis. On 2 occasions in Group
Ventrodorsal radiograph on day 0 (A) versus day 11 (B) confirming similar radiographic placement of the pH capsule using measurement system on capsule delivery device 1 on day 11, the capsules failed to sync with their respective wireless monitor, and, therefore, new capsules were replaced in the gastric fundus without complications. With respect to adhered capsules, on 2 occasions (both on day 12, Group 1), the Bravo pH capsule detached and exited the stomach before the end of the monitoring period. Data from these 2 cats therefore were not included in the treatment comparisons on day 13.
| Intragastric pH recordings
Mean intragastric pH and MPT intragastric pH ≥3 and ≥4 in a 24-hour period on days 1 and 13 were used for statistical analyses. These were days in which all groups received treatment, a sufficient number of cats were available based on the sample size calculation, and cats did not undergo sedation. Mean ± SD intragastric pH for cats receiving twice daily (Group 1) or twice daily every second day (Group 2) famotidine at days 0, 1, 13, and 15 are listed in Table 1 . No significant period effects were observed for mean pH or MPT intragastric pH ≥3
and ≥4, thereby indicating that the period of 7 weeks between treatment phases was sufficient (P = .14, P = .43, and P = .22, respectively).
The MPT intragastric pH ≥3 and pH ≥4 on baseline day 0 was 21% ± 4.0% and 16% ± 2.9% for Groups 1 and 2, respectively, and no significant differences were found between treatment groups (P = .43 and P = .42, respectively).
Significant treatment group by time interactions considering days 1 and 13 were observed for mean intragastric pH, MPT intragastric pH ≥3 and pH ≥4 (P = .009, P = .02, P = .005, respectively). Post hoc analyses identified a significant decrease in mean intragastric pH of 1.5 on day 13 compared to day 1 for cats in Group 1 (P = .001). The MPT intragastric pH ≥3 on days 1-3 and 11-13 (shown in Figure 2) highlight the decrease in intragastric pH over time within Group 1. A 31% decrease in MPT intragastric pH ≥3 and a 27% decrease for untransformed MPT intragastric pH ≥4 between days 1 and 13 (P = .0007 and P = .0008, respectively) were observed for Group 1.
No significant differences were found in mean intragastric pH (P = .90) and MPT intragastric pH ≥3 and ≥4 (P = .84 and P = .78, respectively) on treatment day 13 compared to day 1 in Group 2. On days in which cats did not receive treatment (eg, days 2 and 12) in Group 2, mean intragastric pH decreased ( Figure 2 ). Mean pH and MPT intragastric pH ≥3 and ≥4 for all groups on days 1 and 13 are shown in Figure 3 .
Regarding statistical comparisons between Groups 1 and 2, interaction post hoc tests identified a marginally significant difference in mean intragastric pH between treatment groups on day 1 (P = .03)
but not for MPT intragastric pH ≥3 and ≥4 (P = .15 and P = .30). Significant differences were found between Groups 1 and 2 observed on day 13 for both MPT intragastric pH ≥3 and 4 (P = .03 and P = .005, respectively) but not on day 1. When comparing between treatments exclusively on day 13, a marginal significant difference in mean intragastric pH was observed (P = .05). This resulted in an overall mean decrease in pH of 0.75 in Group 1 compared to Group 2.
| Serum gastrin concentrations
The reference range for serum gastrin concentration in cats was established as <10.0-39.5 pg/dL. 13 Serum gastrin concentrations (Table 2) increased significantly across time regardless of treatment received (P < .0001). Post hoc tests identified significant differences between baseline (day 0) concentrations and those on treatment days 2 (P < .0001) and 11 (P = .0002). No significant difference was found between or within treatments on days 2 or 11 (P = .59). No carryover effects were observed for serum gastrin concentrations (ie, no significant difference was found between treatment groups on day 0; P = .87).
| Rebound hyperacidity
When available (n = 7, Group 1; n = 11, Group 2), data on day 15 were compared to baseline (day 0) to evaluate for rebound gastric hyperacidity after cessation of famotidine administration. No significant No significant differences were observed between treatment groups on day 0 (P = .56). There was a marginally significant difference in mean intragastric pH between treatment groups on day 1 (P = .03). Mean intragastric pH was significantly decreased on day 13 compared to day 1 in Group 1 (P = .001) but not in Group 2 (P = .90). There was a marginal significant difference (P = .05) in mean intragastric pH between groups on day 13. Data is reported on days for which a minimum of 13 cats were available for measurement (Group 1: day 0-3, n = 16, day 11-12: n = 15, day 13: n = 13; Group 2: day 0-1: n = 16, day 2-3: n = 14, day 11-13: n = 15). Days 2 and 12 are nontreatment days for Group 2.* MPT intragastric pH ≥3 was significantly decreased on day 13 compared to day 1 in Group 1 (P = .0007) but not in Group 2 (P = .84). There was a significant difference between groups on day 13 (P = .03) differences were observed on day 15 compared to day 0 for either group with regard to mean pH (P = .12 for Group 1; P = 0.95 for Group 2),
MPT intragastric pH ≥3 (P = .11 for Group 1; P = .30 for Group 2), or
MPT intragastric pH ≥4 (P = .28 for Group 1; P = .18 for Group 2). The absolute number of episodes the mean fecal scores were >4 were 13 (Group 1) and 11 (Group 2). One cat inadvertently missed half of a dose of famotidine on day 2 in Group 1. Data from this day was not included. One cat was excluded from the study early because of its fractious temperament and inability to receive famotidine consistently. This cat's data was included for statistical analysis on day 1 for both groups, but a complete data set was not available for comparison on day 13. Neither inclusion nor exclusion of this cat impacted the results.
| Adverse events
| DISCUSSION
We evaluated the effect of twice daily (Group 1) and twice daily every second day (Group 2) oral famotidine administration on intragastric pH in cats to determine if a diminished acid suppressing effect, or tolerance, develops over time. Maintaining the MPT intragastric pH ≥3 and 4 for approximately 75% and 67% of the day has been demonstrated to predict tissue healing in human patients with duodenal ulceration and acid-induced esophagitis, respectively, and thus were used, in addition to mean intragastric pH, for comparative analyses. 15, 16 In our study, MPT intragastric pH ≥3 and pH ≥4 on baseline day 0 was similar to baseline data for the placebo group in a previous study of famotidine administration in cats. 1 Cats in Group 1 had a significant decrease in mean intragastric pH and MPT intragastric pH ≥3
or ≥4 on treatment day 13 compared to day 1. In Group 1, famotidine administration resulted in a MPT intragastric pH ≥3 of 52% and an
MPT intragastric pH ≥4 of 38% on day 1. By day 13, these had decreased to 21% and 11%, respectively. Therefore, famotidine (n = 15) (n = l5)
Statistical comparisons were performed with data from days 0, 2, and 11. Significant differences in gastrin are observed between days 0 and 2 (P < .0001), days 0 and 11 (P = .0002), but not between days 2 and 11 (P = .59) administration did not meet the clinical acid-suppressing goals for the treatment of acid-related disorders on day 1 nor over time in Group 1. This finding of diminished famotidine efficacy is consistent with a previous study of twice daily oral famotidine administration over 7 days in healthy cats. 1 This effect might occur earlier than day 13.
However, statistical analyses were not performed before this time because of the effect of sedation and fasting on gastric pH on day 11 and lack of a large enough sample size on days earlier than day 11.
On day 1, there was a marginally significant difference in mean intragastric pH but not MPT pH ≥3 or 4, meaning this finding is likely not clinically relevant.
There were no significant differences in mean intragastric pH and MPT intragastric pH ≥3 and ≥4 on day 13 compared to day 1 in Group 2. Group 2 cats had an MPT intragastric pH ≥3 of 41% on day 1 compared to 40% on day 13 and a MPT intragastric pH ≥4 of 27% on day Serum gastrin concentrations significantly increased with famotidine, regardless of treatment frequency. By day 11, gastrin concentrations had not returned to baseline. This finding is in contrast to dogs, in which serum gastrin concentrations transiently increased but returned to baseline by day 12 of famotidine administration. 21 Based on these data, we believe that famotidine still may be imparting an effect, albeit negligible, on gastric pH in cats on day 11. The effect of sedation, as performed on days 0 and 11, on serum gastrin concentrations is unknown and warrants further study.
Rebound acid hypersecretion is defined as gastric acid secretion above the pretreatment baseline after withdrawal of acid suppressant treatment. 22, 23 In people, H2RAs induce a short-lived and clinically insignificant RAH compared to PPIs. 22 To our knowledge, RAH has not been evaluated previously with H2RA administration in cats. We did not detect overt RAH after abrupt cessation in either group based on the analysis of baseline day 0 to day 15 data. However, we did not measure gastric acid secretion and cannot definitely say that abrupt cessation of famotidine does not induce RAH. Moreover, our evaluation for RAH was underpowered because most pH capsules had passed out of the stomach by day 15 (n = 9, Group 1; n = 5, Group 2). An additional study with a larger sample size would be required to confirm our findings.
In conclusion, ours is the first study to demonstrate that tolerance occurs over time with oral famotidine administration in healthy colony cats at the dosages studied. This effect appears to be dependent on dose or daily administration of famotidine. Additional studies are needed to determine if the tolerance phenomenon develops in clientowned cats with metabolic, inflammatory, and neoplastic diseases.
However, until such studies are performed, we do not recommend long-term, twice daily oral administration of famotidine in cats because it loses its acid-suppressing effect over time.
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